絞り込み

16548

広告

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios.

著者 Chang TY , Liao JN , Chao TF , Vicera JJ , Lin CY , Tuan TC , Lin YJ , Chang SL , Lo LW , Hu YF , Chung FP , Chen SA
Int J Cardiol Heart Vasc.2018 Sep ; 20():56-62.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (50view , 0users)

Full Text Sources

Miscellaneous

Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X, has been recommended for stroke prevention for decades. Non-Vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban and edoxaban are at least as effective as warfarin in reducing ischemic stroke with a lower rate of major bleeding. With the increasing prevalence of AF, prescription of the appropriate oral anticoagulants (OACs) according to patient's characteristics becomes a challenge. This review article aims to provide an overview of anticoagulant use in AF patients with difficult scenarios.
PMID: 30186937 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード